JERSEY CITY, N.J.--(BUSINESS WIRE)--Exalenz Bioscience (TASE: EXEN), developer of the BreathID®, an advanced diagnostic system that uses a patient’s breath to quickly and easily identify and manage specific digestive and liver conditions, announced today that industry expert Ted Foltyn has joined the company as its new vice president of worldwide marketing and business development. Today’s news follows the March 2013 appointment of the company’s new CEO Mr. Lawrence Cohen and the May 2013 FDA market clearance of the company’s next generation BreathID technology in the U.S.
“Exalenz is gearing up for the quickly approaching market launch of the new generation BreathID Hp. Part of this means expanding our marketing and business development team. We warmly welcome Ted to the Exalenz family. We are certain that the company will greatly benefit from his clear vision, outstanding guidance and many years of industry success,” said Exalenz CEO Mr. Lawrence Cohen.
Mr. Foltyn is a mentor at the University of Delaware’s National Science Foundation, Innovation Corps Program and the former senior director of sales and marketing at Johnson and Johnson, where he managed a $12MM annual budget and led among other successful initiatives, the commercialization effort for VERV®, a first-to-market neuromodulation device. He was honored by the company with the prestigious OMP OPTIMUS Award for Consistently Outstanding Leadership. Mr. Foltyn received five J&J Standards of Leadership Awards during his tenure.
Prior to this, Mr. Foltyn worked for two J&J owned companies. He served as vice president of worldwide marketing for Ethicon Women’s Health and Urology. He also held a series of managerial sales and marketing positions at Ortho-McNeil Pharmaceuticals, the last being director of product development. Mr. Foltyn earned a B.S. in economics from the University of Delaware and an MBA in finance from Northeastern University.
“BreathID is truly a remarkable device. It quickly and accurately determines if a patient has H. pylori, a bacteria that causes various illnesses. As test results are available almost immediately, physicians are able to promptly treat patients as well as continuously and easily monitor them for eradication of the bacteria,” said Mr. Foltyn. “It is with great pleasure that I join Exalenz. I look forward to working together with the talented and driven team, under the astute and focused leadership of CEO Mr. Lawrence Cohen. Together we will creatively drive company growth and increase our presence in the U.S. using various tools including education.”
About Exalenz Bioscience
Exalenz Bioscience develops medical equipment that uses the breath to diagnose and help manage digestive system and liver conditions by identifying the presence of the H. pylori bacteria, the cause of various illnesses. To date, blood tests or stool samples have been used to detect the same, in uncomfortable procedures which have limited accuracy and which require days to secure results. The company’s flagship product, the BreathID, is patient and technician friendly, provides results in a matter of minutes, and is clinically proven to be extremely accurate. Unlike the competition, the BreathID takes continuous samples of breath and operation is as simple as pushing one button. The BreathID system is FDA cleared and has a CE mark.
For more information: www.exalenz.com
Follow
us on Twitter.
Watch
our product
video.
This news release may contain “forward-looking statements.” Statements in this press release, which are not purely historical, are forward-looking statements including statements concerning the Company’s business outlook or future economic performance, anticipated revenues, expenses or other financial items, plans and objectives related thereto, and assumptions or expectations relating to any future events, conditions, performance or other matters. Forward-looking statements are subject to risks, uncertainties and factors including, but not limited to, changing customer demands, changing regulatory requirements, customer acceptance of the Company's products, the impact of competitive products and pricing, dependence on existing management, that technology may not function as expected and general economic conditions. The Company assumes no obligation to update the information in this release.
